Persavita Inc. is pleased to announce the successful issue of the United States patent for its flagship natural eye health product, Saffron 2020.
Saffron 2020 is a nutritional supplement that is approved to help maintain general eyesight and to support eye health in aged-related macular degeneration (AMD) and cataracts. The U.S. patent (number 9,486,464) recognizes the unique benefits for AMD of the combination of saffron and resveratrol that helps make the Saffron 2020 formula so effective.
"We know Saffron 2020 is special, and we are thrilled to reach this milestone" says Persavita CEO Dr. Mahmood Piraee, PhD, PharmD. "We've witnessed amazing outcomes among people taking Saffron 2020, and the patent allows Persavita to offer it to more people suffering from AMD or trying to maintain their general eye health."
Loss of eyesight is a growing concern in our society. Sun exposure and blue light from our electronic devices both have a negative effect on eye health and threaten to perpetuate vision loss. As we live longer lives, the consequences of ignoring our eye health could be disastrous. Saffron 2020 plays a key role for maintaining eyesight in healthy individuals and in those affected by AMD.
Saffron 2020's vegetarian, gluten-free capsules safely provide precise, optimal levels of the most important eye health ingredients, including 20mg of highest quality saffron. Saffron is a "super spice" that is clinically shown to improve vision in patients with dry form of AMD by changing the way genes work together to repair and maintain cells in the retina of the eye.
Saffron 2020 also contains resveratrol, another gene-modulating, natural ingredient that helps protect our retina, and macular carotenoids called lutein and zeaxanthin, which have been shown to meaningfully affect visual performance.
No other product offers this synergistic combination of scientifically proven ingredients for the maintenance of good eyesight.
Federal funding boosts effort to make eye transplants a reality